Profit from the New
Frontier
in Healthcare

Request our Latest Information Document on Medical Cannabis, one of the Fastest-Growing Disruptive Investment Opportunities of 2023.

Invest in Medical Cannabis





Savvy investors understand the significance of incorporating environmental, social, and governance (ESG) investments into their portfolios. Over the past five years, the Medical Cannabis sector has been uniquely linked to these core values. Investors are progressively applying these non-financial factors to their analysis in determining material risk and growth opportunities.

Request our Latest Information Document on Medical Cannabis, one of the Fastest-Growing Disruptive Investment Opportunities of 2023.

Why invest now


With proof of concept and product-market fit, this industry's growth is a natural point for investors chasing exceptional returns and decreased risk.



  • Founded in 2019 by an experienced Management Team and Medical Professionals
  • Fully licensed and compliant businesses
  • Ethical, cannabis-based prescriptive-only products developed for humans and animals
  • UK Group with a physical presence in Germany, Portugal, South Africa & Colombia
  • Partnered with Europe’s largest hospital and a Publicly listed Healthcare Company
  • 3 fully licensed indoor cultivation facilities, currently constructing Europe's 2nd largest
  • Licensing agreement to supply CBD-based chemotherapeutics alongside Maintrac Cancer Diagnostic Technology
  • Global shift, disrupting prescriptive healthcare
  • EU state healthcare systems serve a population of 760m people
  • The industry will more than double in size within the next five years

For instance, seed investors often seek up to 30x to 50x returns, series A investors target 10x returns, and late-stage investors expect 3x returns.


Healthcare Revolution


Our FREE Information Document will Offer Insight into How this Natural Plant is Transforming our Approach to Healthcare.




So, why now? The sector is only now beginning to recognise its full potential. The industry will more than double over the next five years. Estimates foresee the legalised market size across Europe reaching 89 million users.

Mother nature's green leaf not only yields a viable alternative to Big Pharma healthcare with the treatment of Cancer, Epilepsy, Multiple Sclerosis, and ADHD, but it is also well-documented that its sister leaf "Hemp" is the only perennial renewable natural resource capable of supplying the world's textile, transit, and energy needs while rebuilding the soil, reducing pollution, and cleansing the atmosphere.